-0.69%
6.34%
13.03%
-4.63%
-2.88%
-43.12%
7.82%
AI Spotlight on ERF
Company Description
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products.It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics.
In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing.Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services.Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services.
It operates approximately 900 laboratories in 54 countries.The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Market Data
| Last Price | 51.86 |
| Change Percentage | -0.69% |
| Open | 52.24 |
| Previous Close | 52.22 |
| Market Cap ( Millions) | 9924 |
| Volume | 440391 |
| Year High | 62.1 |
| Year Low | 39.47 |
| M A 50 | 48.2 |
| M A 200 | 51.16 |
Financial Ratios
| FCF Yield | 6.58% |
| Dividend Yield | 0.96% |
| ROE | 5.27% |
| Debt / Equity | 64.79% |
| Net Debt / EBIDTA | 205.25% |
| Price To Book | 1.91 |
| Price Earnings Ratio | 39.12 |
| Price To FCF | 15.2 |
| Price To sales | 1.48 |
| EV / EBITDA | 9.55 |
News
- Jan -31 - Eurofins Scientific SE (ERFSF) Full Year 2024 Earnings Call Highlights: Strong Revenue Growth ...
- Jan -30 - Eurofins Achieves New Record Level of Annual Revenues While Demonstrating a Strong Increase in Margins and Cash Generation and Returns to Its Pre-COVID Profitability and Cash Flow Growth Trends
- Jan -21 - Eurofins Environment Testing Eaton Analytical Launches Groundbreaking Chloronitramide Anion Testing for Drinking Water
- Jan -17 - CORRECTING and REPLACING: Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 December 2024
- Jan -16 - Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 December 2024
- Dec -20 - Eurofins Launches Fourth Buy-Back Programme of Its Own Shares
- Dec -05 - Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 November 2024
- Nov -25 - Eurofins Sustainability Services Introduces CleanAir Check Service for Volatile Organic Compounds (VOCS) Testing
- Nov -13 - Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 October 2024
- Oct -28 - Eurofins Agrees to Acquire SYNLAB’s Clinical Diagnostics Operations in Spain
- Oct -22 - Eurofins Announces Results of Cash Audit Confirming Its FY 2023 Cash Balance and the High Integrity of Its Systems and Controls and Refutes Muddy Waters’ Allegations Regarding Transactions That Occurred Between 10 and 25 Years Ago
- Oct -22 - Eurofins Confirms Profitability and Cash Flow Objectives for 2024 Leading to Higher Profit Margins in Spite of the Impact of the Post-COVID Reset of BioPharma Pipelines
- Oct -21 - Eurofins: Purchases of Own Shares from October 14th to October 18th, 2024
- Oct -14 - Eurofins: Purchases of Own Shares From October 7th to October 11th, 2024
- Oct -10 - Eurofins Discovery Extends AI-powered Integrated Drug Discovery Collaboration
- Oct -07 - Eurofins: Purchases of Own Shares From September 30th to October 4th, 2024
- Oct -04 - Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 September 2024
- Sep -30 - Eurofins: Purchases of Own Shares from September 23th to September 27th, 2024
- Sep -24 - Eurofins CDMO Alphora Inc. Announces Construction of GMP Biologics Manufacturing Facility
- Sep -24 - Eurofins Sustainability Services Introduces EUDR Deforestation Impact Assessment
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Sample-based
Expected Growth : 6 %
What the company do ?
Sample-based testing from Eurofins Scientific SE involves analyzing physical samples to detect and quantify contaminants, residues, and other substances in food, pharma, and environmental products.
Why we expect these perspectives ?
Eurofins Scientific SE's 6% growth is driven by increasing demand for bioanalytical services, expansion in emerging markets, and strategic acquisitions. The company's leadership in genomic and precision medicine, as well as its commitment to innovation and R&D, also contribute to its growth momentum.
Segment n°2 -> Study-based
Expected Growth : 5 %
What the company do ?
Study-based services from Eurofins Scientific SE provide comprehensive testing, inspection, and certification solutions for industries such as pharmaceuticals, food, and environment.
Why we expect these perspectives ?
Eurofins Scientific SE's 5% growth is driven by increasing demand for bioanalytical services, expansion in emerging markets, and strategic acquisitions. The company's leadership in genomics and proteomics, as well as its investment in digitalization and automation, also contribute to its growth. Furthermore, the rising need for quality control and assurance in the food and pharmaceutical industries supports Eurofins' growth momentum.
Segment n°3 -> Full Time Equivalent-based
Expected Growth : 8 %
What the company do ?
Full Time Equivalent (FTE) is a metric used by Eurofins Scientific SE to measure the number of full-time employees, considering part-time workers as a proportion of a full-time worker.
Why we expect these perspectives ?
Eurofins Scientific SE's 8% growth in Full Time Equivalent (FTE) is driven by increasing demand for biopharmaceutical and genomics services, expansion into emerging markets, strategic acquisitions, and investments in digitalization and automation, leading to improved operational efficiency and enhanced customer experience.
Segment n°4 -> Product-based
Expected Growth : 9 %
What the company do ?
Eurofins Scientific SE's Product-based segment provides testing, inspection, and certification services for a wide range of products, including food, pharmaceuticals, and consumer goods.
Why we expect these perspectives ?
Eurofins Scientific SE's 9% growth is driven by increasing demand for bioanalytical testing, expansion in emerging markets, and strategic acquisitions. The company's diversified product portfolio, including genomic services and food safety testing, also contributes to growth. Additionally, investments in digitalization and automation enhance operational efficiency, further supporting revenue expansion.
Segment n°5 -> Other
Expected Growth : 4 %
What the company do ?
The 'Other' segment from Eurofins Scientific SE includes various businesses such as forensics, genomics, and food and pharma products testing.
Why we expect these perspectives ?
Eurofins Scientific SE's 4% growth is driven by increasing demand for biopharmaceutical and genomics services, expansion into emerging markets, and strategic acquisitions. Additionally, growing regulatory requirements and outsourcing trends in the pharmaceutical industry contribute to the company's growth.
Eurofins Scientific Se Products
| Product Range | What is it ? |
|---|---|
| Pharmaceutical Products Testing | Eurofins Scientific SE provides testing services for pharmaceutical products, including raw materials, intermediates, and finished products, to ensure compliance with regulatory requirements and quality standards. |
| Food Safety Testing | Eurofins Scientific SE offers testing services for food and beverages, including microbiological, chemical, and physical testing, to ensure compliance with food safety regulations and standards. |
| Environmental Testing | Eurofins Scientific SE provides testing services for environmental samples, including air, water, and soil, to monitor and assess environmental pollution and contamination. |
| Genomics and Proteomics Services | Eurofins Scientific SE offers genomics and proteomics services, including DNA sequencing, gene expression analysis, and protein analysis, for research and development, and diagnostic applications. |
| Agroscience Services | Eurofins Scientific SE provides testing services for the agroscience industry, including crop protection, seed testing, and agricultural product testing, to ensure compliance with regulatory requirements and quality standards. |
| Cosmetics and Personal Care Testing | Eurofins Scientific SE offers testing services for cosmetics and personal care products, including safety and efficacy testing, to ensure compliance with regulatory requirements and quality standards. |
Eurofins Scientific SE's Porter Forces
Threat Of Substitutes
Eurofins Scientific SE operates in a highly specialized industry, and the threat of substitutes is moderate. While there are some alternative testing and analytical services available, they are not easily substitutable, and Eurofins' strong reputation and expertise provide a competitive advantage.
Bargaining Power Of Customers
Eurofins Scientific SE has a diverse customer base, and no single customer accounts for a significant portion of its revenue. This reduces the bargaining power of customers, and Eurofins is able to maintain a strong negotiating position.
Bargaining Power Of Suppliers
Eurofins Scientific SE relies on a network of suppliers for equipment, reagents, and other inputs. While there are some alternative suppliers available, the company's scale and reputation provide some bargaining power, but suppliers still have some negotiating leverage.
Threat Of New Entrants
The laboratory testing and analytical services industry has high barriers to entry, including significant capital expenditures, regulatory hurdles, and the need for specialized expertise. This limits the threat of new entrants and provides a competitive advantage to established players like Eurofins Scientific SE.
Intensity Of Rivalry
The laboratory testing and analytical services industry is highly competitive, with several established players competing for market share. Eurofins Scientific SE faces intense competition from rivals, which can lead to pricing pressure and the need for continuous innovation and investment.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 52.41% |
| Debt Cost | 3.95% |
| Equity Weight | 47.59% |
| Equity Cost | 6.94% |
| WACC | 5.37% |
| Leverage | 110.13% |
Eurofins Scientific SE : Quality Control
Eurofins Scientific SE passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| QIA.DE | QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for … |
| SYAB.DE | SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers … |
| BIM.PA | bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers … |
| DIA.MI | DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ipsen
A-Score
1-Year Total Return ->
🥈
Synlab
A-Score
1-Year Total Return ->
🥉
DiaSorin
A-Score
1-Year Total Return ->
4
Qiagen
A-Score
1-Year Total Return ->
5
bioMérieux
A-Score
1-Year Total Return ->
6
